The 2009 ICMlC PA calls for maintaining "development of novel imaging agents and technologies ... in a highly multidisciplinary environment "... with "...."involvement of clinician scientists in all aspects of ICMIC-supported research." The 2010-2015 UCLA ICMlC goals are consistent with these NCI-ICMIC objectives. The PA Research Projects call for "multi-disciplinary interactions among investigators focused on the ultimate goal of discovering, developing, and translating molecular imaging technologies, imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pathology, pharmacology, computational sciences, and biomedical engineering". Our proposed projects each focus on a specific disease (Ribas, melanoma;Radu, lymphoma;Wu, soft tissue sarcoma;Herschman, colon cancer). They combine cell biology, specific mouse models for pre-clinical translation, and ongoing or proposed clinical trials of new delivery systems, new imaging probes or multi-modality imaging combinations to stratify patients, predict response to therapy and/or monitor response to alternative therapies. They involve collaborations among basic researchers using animal models, pathologists, radio-chemists, instrumentation engineers, statisticians, clinical oncologists and nuclear medicine experts. The PA proposes that Developmental projects "stimulate interdisciplinary collaborations, while addressing promising emerging research opportunities". Our proposed projects are relatively high risk proposals that consider new approaches to imaging therapy (Kasahara), switching glucose metabolism in tumors (Chrisofk), monitoring alternative metabolic pathways possibly critical for tumor development (Bensinger) and a new way, not dependent on substrate-enzyme or ligand-receptor interactions, to identify potential imaging probes (Huang). Two 2010 Research projects grew directly from former Developmental projects. We continue and expand the service of our ICMlC Specialized Resources, but add no new Specialized Resources. We continue our Career Development program, funding highly qualified scholars in whom investment to work on molecular imaging problems will, we feel, provide a career-changing experience. The overriding goals of our Research Components, Developmental Funds, Career Development training, Specialized Resources and ICMlC meetings and seminars are (i) to foster incorporation of non-invasive molecular imaging to the best cancer research at UCLA, and (ii) to provide resources to encourage translation of molecular imaging principles and practice to cancer diagnosis, management and therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Program Officer
Menkens, Anne E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Jiao, Jing; Ishikawa, Tomo-O; Dumlao, Darren S et al. (2014) Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer. Mol Cancer Res 12:1677-88
Jiao, Jing; Mikulec, Carol; Ishikawa, Tomo-o et al. (2014) Cell-type-specific roles for COX-2 in UVB-induced skin cancer. Carcinogenesis 35:1310-9
Shurell, Elizabeth; Tran, Linh M; Nakashima, Jonathan et al. (2014) Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer 14:827
Mongini, Patricia K A; Kramer, Jill M; Ishikawa, Tomo-O et al. (2014) Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice. Clin Immunol 153:79-90
Wilks, Moses Q; Knowles, Scott M; Wu, Anna M et al. (2014) Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging. J Nucl Med 55:1539-44
Schwarzenberg, Johannes; Czernin, Johannes; Cloughesy, Timothy F et al. (2014) Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res 20:3550-9
Wardak, Mirwais; Schiepers, Christiaan; Cloughesy, Timothy F et al. (2014) ¹?F-FLT ???and ¹?F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging 41:1199-209
Nathanson, David A; Armijo, Amanda L; Tom, Michelle et al. (2014) Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med 211:473-86
Hirata, Kenji; Kobayashi, Kentaro; Wong, Koon-Pong et al. (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 9:e105682
Escuin-Ordinas, Helena; Atefi, Mohammad; Fu, Yong et al. (2014) COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol 8:250-60

Showing the most recent 10 out of 184 publications